Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron, the active ingredient in Ondansetron Kabi, is a 5‑HT3 receptor antagonist presented as an intravenous solution for intravenous use. It is employed to prevent and treat nausea and vomiting that can occur after chemotherapy, radiotherapy, or surgery, providing a rapid anti‑emetic effect in adult patients.

GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality‑controlled batches that meet EU regulatory standards and providing comprehensive logistics support and documentation for cross‑border procurement.

Ondansetron Kabi is a 5‑HT3 receptor antagonist used to manage nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of both acute and delayed episodes in patients receiving cytotoxic agents. - Radiotherapy‑induced nausea and vomiting: helps control nausea associated with radiation treatment, improving patient comfort during therapy. - Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures, facilitating faster recovery and discharge.

Like all medications, Ondansetron Kabi may be associated with adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity, often transient and resolves without intervention. - Constipation: reduced bowel movements that may cause abdominal discomfort. - Dizziness: transient light‑headedness, usually resolving within a short period. - Fatigue: feeling of tiredness that can affect daily activities.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT interval prolongation that can lead to serious rhythm disturbances. - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention. - Serotonin syndrome: agitation, hyperreflexia, fever and other neuromuscular signs in susceptible patients.

Before initiating therapy, clinicians should consider several safety measures.

- Assess cardiac risk: evaluate baseline ECG for QT prolongation. - Monitor electrolytes: correct hypokalemia or hypomagnesemia prior to administration. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid concurrent use with other QT‑prolonging agents unless benefits outweigh risks. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron Kabi can interact with other medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Other QT‑prolonging drugs: increased risk of arrhythmia. - Apomorphine: may cause severe hypotension and loss of consciousness.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Anticholinergic agents: may diminish anti‑emetic effect.